Physician profile
Vinod Kapoor
NPI 1053457986
$20,887.87
in general payments reported to CMS, 2019-2025
55 companies · $2,359 in 2025
The $2,359 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,211 · 2020: $1,375 · 2021: $3,151 · 2022: $2,972 · 2023: $3,611 · 2024: $3,209 · 2025: $2,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,092 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,091.69 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $7,731.42 | 2019-2024 | Mavenclad, Mavenclad |
| Abbvie INC. | $2,032.41 | 2021-2025 | |
| Medtronic, INC. | $938.90 | 2022-2025 | Visualase, Corevalve Evolut R |
| Sk Life Science, INC. | $762.08 | 2020-2024 | Xcopri |
| Monteris Medical Corporation | $659.20 | 2019 | |
| Biogen, INC. | $633.49 | 2019-2024 | Vumerity, Tysabri, Leqembi |
| Tg Therapeutics, INC. | $574.34 | 2023-2025 | |
| Lundbeck LLC | $489.43 | 2021-2024 | Vyepti |
| Neurocrine Biosciences, INC. | $483.12 | 2019-2025 | Ingrezza |
| Pfizer INC. | $477.28 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $451.46 | 2021 | |
| Ucb, INC. | $432.23 | 2019-2024 | Briviact |
| Celgene Corporation | $410.61 | 2021-2023 | Zeposia |
| Axsome Therapeutics, INC. | $341.02 | 2025 | Symbravo |
| Lilly USA, LLC | $339.75 | 2019-2024 | Kisunla, Emgality, Reyvow |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinod Kapoor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.